偶发胆总管扩张行超声内镜评估时显著发现临床预测因素
在两个学术医疗中心连续纳入无活动性胰胆疾病且肝功能无显著升高的偶发胆总管扩张患者,行超声内镜检查。375例中31例(8.3%)有显著发现,多变量分析确定年龄≥70岁、非胆源性无慢性腹痛、胆总管直径≥15 mm或胆囊切除术后≥17 mm及既往ERCP为预测因素,并建立经验证的新预测模型。
要点
- 偶发胆总管扩张患者EUS显著发现率低于10%(8.3%)。
- 年龄≥70岁、非胆源性无慢性腹痛、既往ERCP及胆总管显著扩张为预测因素。
- 新预测模型评分<1分可排除需EUS者约30%,≥4分对显著病变特异性>90%。
核心结论
- 偶发胆总管扩张行EUS者不足10%有病理发现,新外部验证预测模型或可减少近三分之一患者的低产出侵入性评估。
研究设计与样本
- 来自2个学术医疗中心连续纳入因偶发胆总管扩张(放射科医师判定客观>6 mm)行EUS、无活动性胰胆疾病且肝功能无显著升高的患者。
- 采用多变量逻辑回归确定EUS显著发现的预测因素,在一个中心建立新预测模型,经自举法内部验证并在第二中心外部验证。
主要发现
- 375例中31例(8.3%)有显著发现,包括26例胆总管结石、1例壶腹部腺瘤和1例胰腺肿块。
- 年龄≥70岁OR 3.7(95%CI 1.5-10.0)、非胆源性无慢性腹痛OR 6.1(95%CI 2.3-17.3)、胆总管直径≥15 mm或胆囊切除术后≥17 mm OR 6.9(95%CI 2.7-18.7)、既往ERCP OR 6.8(95%CI 2.1-22.5)。
- 评分<1分在开发队列敏感性93%、验证队列100%,两队列预测显著发现概率<2%,且两队列约30%可免于EUS。
- 评分≥4分对显著病变存在特异性>90%。
关键数值与推荐
- 新预测模型评分:年龄≥70岁=1分,非胆源性无慢性腹痛=2分,既往ERCP=2分,胆总管扩张=2分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Although EUS is highly accurate for the evaluation of common bile duct (CBD) dilation, the yield of EUS in patients with incidental CBD dilation is unclear. METHODS: Serial patients undergoing EUS for incidental, dilated CBD (per radiologist, minimum of >6 mm objectively) from 2 academic medical centers without active pancreaticobiliary disease or significantly elevated liver function test results were evaluated. Multivariable logistic regression identified predictors of EUS with significant findings and a novel prediction model was derived from one center, internally validated with bootstrapping, and externally validated at the second center. RESULTS: Of 375 patients evaluated, 31 (8.3%) had significant findings, including 26 choledocholithiasis, 1 ampullary adenoma, and 1 pancreatic mass. Predictors of significant findings with EUS included age of ≥70 years (odds ratio [OR], 3.7; 95% confidence interval [CI], 1.5-10.0), non-biliary-type abdominal pain without chronic pain (OR, 6.1; 95% CI, 2.3-17.3), CBD diameter of ≥15 mm or ≥17 mm with cholecystectomy (OR, 6.9; 95% CI, 2.7-18.7), and prior ERCP (OR, 6.8; 95% CI, 2.1-22.5). A point-based novel clinical prediction model was created: age of ≥70 years = 1, non-biliary-type abdominal pain without chronic pain = 2, prior ERCP = 2, and CBD dilation = 2. A score of <1 had 93% (development) and 100% (validation) sensitivity and predicted a <2% chance of having a significant finding in both cohorts while excluding the need for EUS in ∼30% of both cohorts. Conversely, a score of ≥4 was >90% specific for the presence of significant pathology. CONCLUSIONS: Less than 10% of patients undergoing EUS for incidental CBD dilation had pathologic findings. This novel, externally validated, clinical prediction model may reduce low-yield, invasive evaluation in nearly one-third of patients.
引用
- Raza Z, Altayar O, Mahmoud T, et al. Clinical predictors of significant findings on EUS for the evaluation of incidental common bile duct dilation. Gastrointest Endosc. 2024. PMID: 38692515. doi:10.1016/j.gie.2024.04.2902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。